Negative Effect of Intravenous Antibiotics on Survival in Patients with Triple-Negative Breast Cancer
Authors:
- Stefan LukacSLStefan Lukac
- Visnja FinkVFVisnja Fink
- Davut DayanDDDavut Dayan
- Brigitte RackBRBrigitte Rack
- Wolfgang JanniWJWolfgang Janni
- Krisztian LatoKLKrisztian Lato
- Kristina VeselinovicKVKristina Veselinovic
- Sabine HeubleinSHSabine Heublein
- Thomas Wolfram Paul FriedlTFThomas Wolfram Paul Friedl
- Elena LeinertELElena Leinert
Open Access
Abstract
Background: The anti-tumor response of the immune system is pivotal for treating triple-negative breast cancer (TNBC), particularly as targeted therapies are limited. However, the impact of immune-modulating factors such as the application of granulocyte-stimulating factors (G-CSFs) or infections, including febrile neutropenia, prophylactic or therapeutical application of oral antibiotics (OABs), and the need for intravenous antibiotics (IABs), on survival outcomes remains unclear. Methods: 1583 patients with early-stage TNBC enrolled in the SUCCESS A or C study underwent primary surgery, adjuvant chemotherapy, and radiotherapy if indicated. All patients had Eastern Cooperative Oncology Group (ECOG) status ≤ 2. The effects of G-CSF, OAB, and IAB application on overall survival (OS), invasive disease-free survival (iDFS), breast cancer-specific survival (BCSS), and distant disease-free survival (DDFS) were assessed. Results: Only IAB treatment was significantly associated with decreased survival in univariable analyses (OS: p = 0.003; iDFS: p = 0.036; BCSS: p = 0.011; DDFS: p = 0.044), while G-CSF and OAB administration were not. Adjusted multivariable Cox regressions including febrile neutropenia and dose reduction/shift, ECOG, age of patients, and other clinicopathological parameters confirmed a significant negative effect of IABs on OS (p = 0.020), BCSS (p = 0.018), and DDFS (p = 0.044). Conclusions: In summary, IABs during adjuvant chemotherapy seems to be a risk factor for inferior OS, BCSS, and DDFS in TNBC patients, possibly by affecting microbiome-related immune response modulation. Hence, preventive measures to avoid the need for IABs should be considered in these patients.Keywords
This publication has 39 references indexed in Scilit:
- Antibiotic exposure within six months before systemic therapy was associated with lower cancer survivalJournal of Clinical Epidemiology, 2022
- Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancerBreast Cancer Research and Treatment, 2019
- The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancerBiomedicine & Pharmacotherapy, 2018
- Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal WomenJAMA Oncology, 2018
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapyThe Lancet Oncology, 2018
- Gut microbiota modulation of chemotherapy efficacy and toxicityNature Reviews Gastroenterology & Hepatology, 2017
- Clinical relevance of host immunity in breast cancer: from TILs to the clinicNature Reviews Clinical Oncology, 2015
- The microbiome and cancerNature Reviews Cancer, 2013
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008